Phosphatidylserine Cognition Randomized Trial: What the Evidence Says

Quick Answer

Phosphatidylserine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Compared with stimulant medications, atomoxetine has a lower risk of dependence during long-term use. [Shen ZePing (2026); evidence level 4]
• These findings provide supportive evidence for the therapeutic potential of PS in improving ADHD-related symptoms. [Shen ZePing (2026); evidence level 4]
• Phosphatidylserine Supplementation on Psychomotor Speed among Healthy Adults with Subjective Cognitive Declines [Liu Yin (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For phosphatidylserine cognition randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Shen ZePing (2026). The effect of phosphatidylserine on behavioral problems in children with attention deficit hyperactivity disorder. DOI: 10.3389/fpsyt.2026.1661725. PMCID: PMC13056677. PMID: 41960234. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13056677/
• Liu Yin (2025). Phosphatidylserine Supplementation on Psychomotor Speed among Healthy Adults with Subjective Cognitive Declines. DOI: 10.1093/geroni/igaf122.3233. PMCID: PMC12762148. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12762148/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.